The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation.

Delivery of nucleic acids with positively charged lipid nanoparticles ((+)NPs) is widely used as research reagents and potentially for therapeutics due to their ability to deliver nucleic acids into the cell cytoplasm. However, in most reports little attention has been made to their toxic effects. In the present study, we performed comprehensive analyses of the potential toxicity associated with (+)NPs. Mice treated with (+)NPs showed increased liver enzyme release and body weight loss compared to mice treated with neutral or negatively charged NPs ((-)NPs), suggesting hepatotoxicity. Intravenous administration of (+)NPs induced interferon type I response and elevated mRNA levels of interferon responsive genes 15-25-fold higher than neutral and (-)NPs in different subsets of leukocytes. Moreover, treatment with (+)NPs provoked a dramatic pro-inflammatory response by inducing Th1 cytokines expression (IL-2, IFN gamma and TNF alpha) 10-75-fold higher than treatment with control particles. Finally, we showed that activation of TLR4 might serve as the underlying mechanism for induction of an immune response when (+)NPs are used. These results suggest that a careful attention must be made when different types of (+)NPs are being developed as nanotherapeutics.

[1]  Jennifer E. Podesta,et al.  Chapter 17 - Engineering cationic liposome siRNA complexes for in vitro and in vivo delivery. , 2009, Methods in enzymology.

[2]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[3]  Justine R. Smith,et al.  Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 , 2008, Nature.

[4]  Y. Rojanasakul,et al.  Oxygen Radical-Mediated Pulmonary Toxicity Induced by Some Cationic Liposomes , 2000, Pharmaceutical Research.

[5]  Kathryn A. Whitehead,et al.  Lipid-like materials for low-dose, in vivo gene silencing , 2010, Proceedings of the National Academy of Sciences.

[6]  A. Lee,et al.  Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  B. Strukelj,et al.  Potential hepatoprotective effects of fullerenol C60(OH)24 in doxorubicin-induced hepatotoxicity in rats with mammary carcinomas. , 2008, Biomaterials.

[8]  Judy Lieberman,et al.  Interfering with disease: a progress report on siRNA-based therapeutics , 2007, Nature Reviews Drug Discovery.

[9]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[10]  A. Chaudhuri,et al.  Common co‐lipids, in synergy, impart high gene transfer properties to transfection‐incompetent cationic lipids , 2005, FEBS letters.

[11]  David F. Williams On the nature of biomaterials. , 2009, Biomaterials.

[12]  G. Gregoriadis,et al.  Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. , 1980, The Biochemical journal.

[13]  L. Zitvogel,et al.  The immunogenicity of tumor cell death , 2009, Current opinion in oncology.

[14]  W. Shi,et al.  Antitumor and antimetastatic activities of vesicular stomatitis virus matrix protein in a murine model of breast cancer , 2009, Journal of Molecular Medicine.

[15]  L. Zitvogel,et al.  Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. , 2008, Cancer research.

[16]  K. Braeckmans,et al.  The role of nanoparticle concentration-dependent induction of cellular stress in the internalization of non-toxic cationic magnetoliposomes. , 2009, Biomaterials.

[17]  L. Cekaite,et al.  Suppression of immunostimulatory siRNA-driven innate immune activation by 2'-modified RNAs. , 2007, Biochemical and biophysical research communications.

[18]  J. Ruysschaert,et al.  Formation and intracellular trafficking of lipoplexes and polyplexes. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  Marina A Dobrovolskaia,et al.  Nanoparticles and the immune system. , 2010, Endocrinology.

[20]  D. Peer,et al.  RNAi nanoparticles in the service of personalized medicine. , 2009, Nanomedicine.

[21]  D. Peer,et al.  RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  S. Doak,et al.  NanoGenotoxicology: the DNA damaging potential of engineered nanomaterials. , 2009, Biomaterials.

[23]  Pieter van Dokkum,et al.  The nature of , 2006 .

[24]  D. Peer,et al.  Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target , 2008, Science.

[25]  D. Peer,et al.  Systemic siRNA delivery to leukocyte-implicated diseases , 2009, Cell cycle.

[26]  Samuel I. Miller,et al.  LPS, TLR4 and infectious disease diversity , 2005, Nature Reviews Microbiology.

[27]  P. Miossec IL-17 and Th17 cells in human inflammatory diseases. , 2009, Microbes and infection.

[28]  A. Hot,et al.  IL-17 inhibits human Th1 differentiation through IL-12R beta 2 downregulation. , 2009, Cytokine.

[29]  T. Whiteside,et al.  TLR4 signaling induced by lipopolysacharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer , 2009, Oncogene.

[30]  A. Vella,et al.  Understanding how lipopolysaccharide impacts CD4 T-cell immunity. , 2008, Critical reviews in immunology.

[31]  Y. Aramaki,et al.  Lipoxygenase may be involved in cationic liposome-induced macrophage apoptosis. , 2001, Biochemical and biophysical research communications.

[32]  Michael S. Goldberg,et al.  Development of lipidoid-siRNA formulations for systemic delivery to the liver. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  K. G. Rajeev,et al.  Rational design of cationic lipids for siRNA delivery , 2010, Nature Biotechnology.

[34]  H. Park,et al.  Cutting Edge: Direct Interaction of TLR4 with NAD(P)H Oxidase 4 Isozyme Is Essential for Lipopolysaccharide-Induced Production of Reactive Oxygen Species and Activation of NF-κB1 , 2004, The Journal of Immunology.

[35]  Masafumi Nakamura,et al.  Lipopolysaccharide (LPS) increases the invasive ability of pancreatic cancer cells through the TLR4/MyD88 signaling pathway , 2009, Journal of surgical oncology.

[36]  Jiyan Liu,et al.  Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34→Ala mutant , 2008, Journal of experimental & clinical cancer research : CR.

[37]  T. Tuschl,et al.  RNA interference is mediated by 21- and 22-nucleotide RNAs. , 2001, Genes & development.

[38]  Soo-Ho Choi,et al.  Macrophages Generate Reactive Oxygen Species in Response to Minimally Oxidized Low-Density Lipoprotein: Toll-Like Receptor 4– and Spleen Tyrosine Kinase–Dependent Activation of NADPH Oxidase 2 , 2009, Circulation research.

[39]  A. Judge,et al.  Overcoming the innate immune response to small interfering RNA. , 2008, Human gene therapy.

[40]  A. Judge,et al.  siRNA and innate immunity. , 2009, Oligonucleotides.

[41]  L. Coussens,et al.  Cancer: An inflammatory link , 2004, Nature.

[42]  J. Gatot,et al.  DiC14‐amidine cationic liposomes stimulate myeloid dendritic cells through Toll‐like receptor 4 , 2008, European journal of immunology.

[43]  V. Torchilin,et al.  Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)(2) and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy. , 2009, Molecular pharmaceutics.

[44]  H. Rosenberg,et al.  Eosinophil-derived neurotoxin acts as an alarmin to activate the TLR2–MyD88 signal pathway in dendritic cells and enhances Th2 immune responses , 2008, The Journal of experimental medicine.

[45]  D. Peer,et al.  Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models. , 2004, Neoplasia.

[46]  L. Coussens,et al.  De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. , 2005, Cancer cell.

[47]  Miklós Tóth,et al.  Animal Models of Complement-Mediated Hypersensitivity Reactions to Liposomes and Other Lipid-Based Nanoparticles , 2007, Journal of liposome research.

[48]  A. Legat,et al.  DiC14-amidine confers new anti-inflammatory properties to phospholipids , 2008, Cellular and Molecular Life Sciences.

[49]  Chulhee Choi,et al.  Role of NADPH oxidase 4 in lipopolysaccharide-induced proinflammatory responses by human aortic endothelial cells. , 2006, Cardiovascular research.

[50]  Marion Jurk,et al.  Sequences derived from self-RNA containing certain natural modifications act as suppressors of RNA-mediated inflammatory immune responses. , 2009, International immunology.

[51]  A. Sood,et al.  Nanomedicine based approaches for the delivery of siRNA in cancer , 2010, Journal of internal medicine.

[52]  P. Miossec Diseases that may benefit from manipulating the Th17 pathway , 2009, European journal of immunology.

[53]  Matthias John,et al.  RNAi-mediated gene silencing in non-human primates , 2006, Nature.